Education
About Us
Working with TipRanks
Follow Us
XTL Biopharmaceuticals Ltd. Sponsored ADR (XTLB)
NASDAQ:XTLB
RESEARCH TOOLSreports
Total Valuation
XTL Biopharmaceuticals Sponsored ADR has a market cap or net worth of $10.10M. The enterprise value is $10.74M.
Market Cap$10.10M
Enterprise Value$10.74M
Share Statistics
XTL Biopharmaceuticals Sponsored ADR has 8,813,852 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding8,813,852
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
XTL Biopharmaceuticals Sponsored ADR’s return on equity (ROE) is -0.19 and return on invested capital (ROIC) is -29.75%.
Return on Equity (ROE)-0.19
Return on Assets (ROA)-0.12
Return on Invested Capital (ROIC)-29.75%
Return on Capital Employed (ROCE)-0.34
Revenue Per Employee45.10K
Profits Per Employee-102.70K
Employee Count10
Asset Turnover0.05
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of XTL Biopharmaceuticals Sponsored ADR is -13.30. XTL Biopharmaceuticals Sponsored ADR’s PEG ratio is ―.
PE Ratio-13.30
PS Ratio0.00
PB Ratio1.25
Price to Fair Value2.51
Price to FCF0.00
Price to Operating Cash Flow0.00
PEG Ratio―
Income Statement
In the last 12 months, XTL Biopharmaceuticals Sponsored ADR had revenue of 451.00K and earned -1.03M in profits. Earnings per share was -0.15.
Revenue451.00K
Gross Profit3.00K
Operating Income-2.17M
Pretax Income-1.16M
Net Income-1.03M
EBITDA-930.00K
Earnings Per Share (EPS)-0.15
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
XTL Biopharmaceuticals Sponsored ADR pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.94
52-Week Price Change-44.19%
50-Day Moving Average1.22
200-Day Moving Average1.72
Relative Strength Index (RSI)53.19
Average Volume (3m)10.95K
Important Dates
XTL Biopharmaceuticals Sponsored ADR upcoming earnings date is Dec 5, 2023, TBA Not Confirmed.
Last Earnings DateMay 31, 2023
Next Earnings DateDec 5, 2023
Ex-Dividend Date―
Financial Position
XTL Biopharmaceuticals Sponsored ADR as a current ratio of 0.61, with Debt / Equity ratio of 2.54%
Current Ratio0.61
Quick Ratio0.61
Debt to Market Cap0.01
Net Debt to EBITDA0.25
Interest Coverage Ratio-77.57
Taxes
In the past 12 months, XTL Biopharmaceuticals Sponsored ADR has paid -130.00K in taxes.
Income Tax-130.00K
Effective Tax Rate0.11
Enterprise Valuation
XTL Biopharmaceuticals Sponsored ADR EV to EBITDA ratio is -1.47K, with an EV/FCF ratio of -817.01.
EV to Sales3.03K
EV to EBITDA-1.47K
EV to Free Cash Flow-817.01
EV to Operating Cash Flow-844.28
Balance Sheet
XTL Biopharmaceuticals Sponsored ADR has $1.72M in cash and marketable securities with $168.00K in debt, giving a net cash position of -$1.55M billion.
Cash & Marketable Securities$1.72M
Total Debt$168.00K
Net Cash-$1.55M
Net Cash Per Share-$0.18
Tangible Book Value Per Share>-$0.01
Margins
Gross margin is 26.39%, with operating margin of -481.60%, and net profit margin of -227.72%.
Gross Margin26.39%
Operating Margin-481.60%
Pretax Margin-256.54%
Net Profit Margin-227.72%
EBITDA Margin-206.21%
EBIT Margin-250.33%
Analyst Forecast
The average price target for XTL Biopharmaceuticals Sponsored ADR is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast86.44%